Article
Introduction to Medicines for Malaria Venture (MMV)
Search Medline for
Authors
Published: | January 29, 2014 |
---|
Outline
Text
Apart from Artemisinin Combination Therapies (ACTs) there are relatively few effective treatments for Plasmodium falciparum malaria and only one complete treatment for Plasmodium vivax.
This talk will summarize the work of Medicines for Malaria Venture (MMV) and its mission to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.
MMV manages a significant antimalarial pipeline and this has been strengthened in recent years with the delivery of new artemisinin combination therapies, promising new clinical candidates and early stage discovery projects. The talk will explain both the challenges that need to be overcome and the strategy adopted to eradicate the disease, including definitions of target product profiles necessary for asexual blood stage cures (including single dose combination treatment), transmission blocking, vivax and chemoprotection.